Russian government to allow producers to increase prices for vital drugs

20 October 2020
russia_roubles_rubles_money_big

The Russian government will increase the maximum selling prices for some vital and essential drugs available in the domestic market in order to prevent their shortage, reports The Pharma Letter’s local correspondent.

That will be in the form of a special mechanism, that will be designed by the Russian Ministry of Health.

Earlier, a number of pharmaceutical companies had warned the Russian government about their plans to suspend the production and supplies of some drugs, including those from the list of vital medicines to the Russian market due to the low maximum allowable price.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical